News
09-20-2020, 10:06 PM
Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to results from a study at ESMO 2020.
More... (https://www.news-medical.net/news/20200921/Adding-abemaciclib-to-hormonal-therapy-reduces-recurrence-in-patients-with-HR2b-HER2-early-breast-cancer.aspx)
More... (https://www.news-medical.net/news/20200921/Adding-abemaciclib-to-hormonal-therapy-reduces-recurrence-in-patients-with-HR2b-HER2-early-breast-cancer.aspx)